

RECEIVED
CENTRAL FAX CENTER

NOV 29 2006

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-43. (Cancelled)

44. (Currently amended) A method for simultaneous separate ~~multicomponent~~ multiepitope detection of an analyte in a sample, the analyte comprising at least two ~~analyte-specific-components~~ epitopes, comprising the steps of:

(a) providing a solid phase comprising a non-porous support, a first and a second spatially separate test area, and at least a first and a second receptor, the first and second receptors binding specifically with said analyte but to different ~~analyte-specific-components~~ epitopes, the first receptor binding specifically with the analyte via a first ~~analyte-specific-components~~ epitope and the second receptor binding specifically with the analyte via a second ~~analyte-specific-components~~ epitope, the first receptor bound directly or indirectly to the first test area and the second receptor bound directly or indirectly to the second test area, there being no more than one type of analyte-specific receptor bound per test area and there being an inert surface between the test areas which does not bind to the analyte or other sample components,

(b) contacting the sample with the solid phase and with a detection reagent comprising one or more of a third receptor ~~receptors~~ that binds ~~bind~~ specifically with the analyte and that is bound directly or indirectly to a signal generating group, and

(c) separately determining presence or amount of the signal generating group bound to the first or ~~and~~ the second test areas via said analyte, as a measure of the analyte in said sample, wherein a positive test result obtained on one test area is sufficient for indicating the presence of the analyte in said sample.

wherein a single application of the sample is contacted with the solid phase, and wherein the single application of the sample simultaneously contacts the first and second spatially separate test areas.

45. (Currently amended) The method of claim 44 wherein ~~wherein~~ the analyte is selected from the group consisting of HTV I, ~~HEV~~, HTV II, HBV, and HCV-antibodies and HIV antigens.

46. (Previously presented) The method of claim 44 wherein each test area has a diameter of 0.01 to 1 mm.
47. (Previously presented) The method of claim 44 wherein the solid phase further comprises a control area.
48. (Currently amended) The method of claim 44 wherein said detection reagent comprises one or more of a third receptor that binds specifically with the epitope(s) of the analyte and a signal-generating reagent group which is either directly bound to the third receptor or which is a universal detection reagent comprising labelled latex particles which binds to the third receptor.
49. (Currently amended) A solid phase for simultaneous separate ~~multicomponent~~ multi-epitope detection of an analyte in a sample, the analyte comprising at least two ~~analyte-specific components~~ epitopes, the solid phase comprising a non-porous support, a first and a second spatially separate test area, and a first and a second receptor, the receptors binding specifically to the analyte but to different ~~components~~ epitopes of the analyte, the first receptor binding specifically with the analyte via a first ~~analyte-specific components~~ epitope and the second receptor binding specifically with the analyte via a second ~~analyte-specific components~~ epitope, the first receptor bound directly or indirectly to the first test area and the second receptor bound directly or indirectly to the second test area, there being no more than one analyte-specific receptor bound per test area, there being an inert surface between the test areas which does not bind to the analyte or other sample components ~~and wherein an analyte bound to the first test area is not simultaneously bound to the second test area, and wherein a single application of the sample simultaneously contacts the first and second spatially separate test areas, and wherein a positive test result obtained on one test area is sufficient for indicating the presence of the analyte in said sample.~~
50. (Previously presented) The solid phase of claim 49 wherein each test area has a diameter of 0.01 to 1 mm.
51. (Currently amended) A test kit for simultaneous separate ~~multicomponent~~ multi-epitope detection of an analyte in a sample, the analyte comprising at least two ~~analyte-specific components~~ epitopes, the test kit comprising a solid phase according to claim 49 and a detection reagent comprising one or more of a third receptor that binds specifically with the epitope(s) of the analyte and that is bound directly or indirectly to a signal generating group.

52. (Currently amended) The test kit of claim 51 wherein said detection reagent comprises one or more of a third receptor that binds specifically with the epitope(s) of the analyte and a signal-generating reagent group which is a universal detection reagent comprising labelled latex particles which binds to the third receptor.
- 53-72. (Cancelled)
73. (Currently amended) The method of claim 44, wherein the at least two ~~analyte-specific components~~ epitopes in the sample comprise at least two different analyte-specific antigens or at least two different analyte-specific antibodies or at least one analyte-specific antigen and one analyte-specific antibody.
74. (Currently amended) The method of claim 44, wherein the presence or amount of the analyte in said sample is determined by the presence or amount of the signal generating group bound to the first or and the second test areas via the at least two ~~analyte-specific components~~ epitopes and via a test area-specific cut-off.